THMA Pharmacy Growth Priorities 2026: Key Insights for CPOs

Key Takeaways

• The Health Management Academy (THMA) has released 2026 strategic priorities for U.S. health system Chief Pharmacy Officers, emphasizing workforce development and operational resilience as critical drivers of pharmacy growth.
• AI governance, revenue cycle optimization, and workforce retention emerge as interconnected priorities shaping pharmacy operations amid evolving healthcare demands and policy pressures.
• External market pressures—including 340B drug pricing policy changes, outpatient care expansion, and social media-driven demand for specialty medications—directly impact pharmacy revenue and staffing strategies.
• Chief Pharmacy Officers must balance operational efficiency with strategic investments in technology governance and talent management to sustain competitive advantage in 2026.

THMA 2026 Pharmacy Growth Priorities: Strategic Roadmap for Chief Pharmacy Officers

The Health Management Academy (THMA), a membership organization serving U.S. health system executives, has released its 2026 strategic priorities report for Chief Pharmacy Officers. The report, derived from THMA's CXO Priorities insights, identifies workforce and operational strategies as foundational to pharmacy growth in an increasingly complex healthcare environment. Unlike previous years' focus on cost containment alone, the 2026 priorities reflect a shift toward sustainable growth through talent resilience and technology governance.

According to THMA's analysis, Chief Pharmacy Officers face a dual mandate: optimize existing operations while investing in workforce capabilities and artificial intelligence governance frameworks. This strategic rebalancing acknowledges that pharmacy departments cannot achieve growth through efficiency gains alone—they must simultaneously address staffing challenges, implement AI-driven decision-making tools, and navigate evolving reimbursement models.

Workforce Resilience as a Growth Lever

THMA's 2026 report identifies workforce resilience as a primary growth enabler for pharmacy operations. The Academy's insights highlight that Chief Pharmacy Officers must prioritize retention and recruitment strategies to maintain service capacity amid national pharmacist shortages and technician burnout. While specific workforce statistics from the THMA report were not disclosed in publicly available materials, the Academy's broader executive insights emphasize that health system pharmacy departments are competing for talent in a constrained labor market.

The report recommends that Chief Pharmacy Officers develop hybrid workforce models—combining full-time clinical pharmacists with specialized technician roles and expanded automation—to address both capacity and quality concerns. This approach aligns with industry trends showing that health systems investing in workforce development report higher staff retention and improved clinical outcomes in medication therapy management and specialty pharmacy services.

AI Governance and Operational Technology Integration

A significant component of THMA's 2026 priorities addresses artificial intelligence governance in pharmacy operations. The Academy's April 2026 Member Developments update highlighted AI governance frameworks as a critical topic for health system leaders, with direct implications for pharmacy departments managing drug dispensing automation, clinical decision support systems, and supply chain optimization.

Chief Pharmacy Officers are advised to establish governance structures that balance innovation with risk management—ensuring that AI-driven tools for inventory management, drug interaction screening, and patient counseling prioritization are implemented with appropriate clinical oversight and regulatory compliance. The THMA guidance reflects growing regulatory scrutiny of AI use in healthcare and the need for transparent, auditable decision-making processes in pharmacy settings.

Revenue Cycle Optimization Amid Policy Headwinds

THMA's Spring 2026 CFO Forum addressed revenue cycle optimization as a strategic priority, with implications extending to pharmacy operations. The forum covered payer strategies, reimbursement model shifts, and financial sustainability challenges facing health systems. For pharmacy departments, this translates to pressure to optimize medication therapy management billing, specialty pharmacy margins, and 340B drug pricing compliance.

The 340B Drug Pricing Program—which allows eligible health systems to purchase covered outpatient drugs at reduced prices—remains a focal point for Chief Pharmacy Officers. Policy pressures surrounding 340B program audits and potential legislative changes create uncertainty in pharmacy revenue projections. Simultaneously, the expansion of outpatient care and specialty infusion services has compressed traditional pharmacy margins, requiring Chief Pharmacy Officers to identify new revenue streams and operational efficiencies.

External Market Pressures Shaping Pharmacy Strategy in 2026

Policy Pressures on Drug Pricing and Specialty Services

Chief Pharmacy Officers must navigate multiple policy headwinds affecting pharmacy revenue and operations. The 340B program faces ongoing scrutiny regarding manufacturer participation and pricing transparency. Additionally, oncology and infusion services—traditionally high-margin pharmacy services—face reimbursement pressure as payers implement prior authorization requirements and value-based contracting models.

The shift toward outpatient care delivery, accelerated by post-pandemic telehealth adoption and payer incentives, has created both opportunities and challenges for pharmacy departments. While outpatient specialty pharmacy services (including infusion support and medication management) represent growth areas, they also require significant capital investment in clinical staff and infrastructure.

Social Media and Direct-to-Consumer Demand Drivers

An emerging factor influencing pharmacy operations is social media-driven demand for specific medication classes. Research published in 2026 indicates that social media direct-to-consumer advertising (DTCA) and influencer endorsements have increased patient requests for glucagon-like peptide-1 (GLP-1) receptor agonists—including semaglutide (Wegovy, Ozempic)—and sodium-glucose cotransporter-2 (SGLT-2) inhibitors. Clinicians utilizing hybrid virtual and in-person care models reported higher frequencies of such requests compared to traditional in-person-only practices.

For Chief Pharmacy Officers, this trend necessitates workforce planning for specialty pharmacy services, inventory management strategies for high-demand medications, and clinical protocols for counseling patients on appropriate use and potential off-label applications. The increased demand for GLP-1 agonists, in particular, has strained pharmacy supply chains and required expanded clinical pharmacist involvement in patient education regarding cardiovascular and metabolic benefits, as well as potential adverse effects including gastrointestinal side effects and rare pancreatitis risk.

Note: While semaglutide (Wegovy, Ozempic) and related GLP-1 agonists have demonstrated cardiovascular benefits in clinical trials, Chief Pharmacy Officers should ensure that pharmacy protocols include appropriate patient screening, contraindication assessment, and monitoring for adverse effects. These medications are not appropriate for all patients and require individualized clinical decision-making.

THMA Events and Related Strategic Insights for 2026

Spring 2026 CFO Forum: Financial Sustainability and Payer Dynamics

THMA's Spring 2026 CFO Forum provided insights into payer strategies and financial pressures affecting health system operations, including pharmacy departments. The forum addressed revenue cycle optimization, AI governance implementation, and workforce resilience—themes that directly inform Chief Pharmacy Officer strategy. While the forum focused primarily on financial leadership, the discussions on payer contracting models and reimbursement trends have direct implications for pharmacy margin management and specialty service profitability.

April 2026 Member Developments: AI Governance and Workforce Topics

THMA's April 2026 Member Developments update highlighted AI governance frameworks and workforce management as priority topics for health system leaders. The update included industry partner perspectives on implementing AI governance in clinical and operational settings, with particular emphasis on transparency, accountability, and regulatory compliance. For Chief Pharmacy Officers, these insights underscore the importance of developing governance structures before deploying AI-driven pharmacy automation and clinical decision support tools.

Practical Implications for Chief Pharmacy Officers

Strategic Priorities for 2026 Implementation

Based on THMA's 2026 guidance, Chief Pharmacy Officers should prioritize the following strategic initiatives:

• Workforce Development: Implement retention programs, expand technician training pipelines, and evaluate hybrid staffing models combining clinical pharmacists with automation and outsourced services.
• AI Governance: Establish oversight committees for pharmacy automation, clinical decision support systems, and supply chain optimization tools; ensure compliance with emerging regulatory guidance on AI use in healthcare.
• Revenue Cycle Optimization: Audit 340B program compliance, expand specialty pharmacy services with appropriate clinical support, and develop payer contracting strategies for high-demand medication classes.
• Clinical Capacity Planning: Prepare for increased demand for specialty pharmacy services, medication therapy management, and patient counseling—particularly for GLP-1 agonists and other high-profile medication classes.

Balancing Growth with Operational Risk

THMA's 2026 priorities emphasize that sustainable pharmacy growth requires balancing innovation with risk management. Chief Pharmacy Officers must invest in workforce and technology while maintaining clinical quality, regulatory compliance, and financial discipline. This requires cross-functional collaboration with finance, clinical leadership, and IT—areas where THMA's executive forums provide peer benchmarking and best practice sharing.

What to Watch: Emerging Trends and Uncertainties

Several factors will shape pharmacy strategy beyond 2026:

• 340B Program Regulatory Changes: Ongoing legislative and regulatory scrutiny of the 340B program could significantly impact pharmacy revenue for eligible health systems. Chief Pharmacy Officers should monitor policy developments and ensure compliance with current and anticipated requirements.
• GLP-1 Agonist Market Dynamics: Continued social media-driven demand for semaglutide and competing GLP-1 agonists will likely persist, requiring sustained investment in specialty pharmacy capacity and clinical expertise. Payer coverage policies and prior authorization requirements will influence patient access and pharmacy volume.
• AI Regulation and Governance Standards: As regulatory agencies develop clearer guidance on AI use in healthcare, pharmacy departments will need to adapt governance frameworks and documentation practices. THMA and other industry organizations will likely provide updated guidance as standards evolve.
• Workforce Market Dynamics: Pharmacist and technician labor markets remain tight, with geographic variation in availability and compensation pressures. Chief Pharmacy Officers should anticipate continued competition for talent and plan accordingly.

Frequently Asked Questions

References

• The Health Management Academy. "2026 Strategic Priorities for Chief Pharmacy Officers." CXO Priorities Insights. Accessed via hmacademy.com/insights/the-executive-insights-hub/workforce and hmacademy.com/insights/the-executive-insights-hub/artificial-intelligence.
• The Health Management Academy. "Spring 2026 CFO Forum: Payer Strategies, AI Governance, and Revenue Cycle Optimization." Executive Forum Series. Available through THMA membership portal.
• The Health Management Academy. "April 2026 Member Developments: AI Governance Frameworks and Workforce Topics." Member Update. Accessed via hmacademy.com/insights/the-academy-360.
• The Health Management Academy. "Chief Physician Executive Insights: Policy Pressures on 340B Drug Pricing and Specialty Services." Executive Blog. Available at hmacademy.com/blog/chief-physician-executive-cpe.
• National Institutes of Health, National Center for Biotechnology Information. "Social Media Direct-to-Consumer Advertising and Patient Medication Requests: 2026 Analysis." PMC13105398. Published in peer-reviewed healthcare literature addressing DTCA trends and clinical implications.
• JMIR Publications. "Digital Health and Social Media Influence on Medication Requests in Hybrid Care Models." JMIR 2026; 1:e84756. Research on social media-driven demand for specialty medications in virtual and in-person clinical settings.

Disclaimer: This article is based on publicly available THMA insights and industry research current as of April 2026. Specific data points from proprietary THMA reports may be limited in public sources. Chief Pharmacy Officers should consult directly with THMA and regulatory agencies for the most current guidance on 340B compliance, AI governance, and reimbursement policies. Drug information provided is for informational purposes and does not constitute clinical advice; healthcare professionals should consult current clinical guidelines and product labeling for prescribing and dispensing decisions.